2016 Volume 59 Issue 1 Pages 31-35
We investigated the tissue penetration of garenoxacin mesilate hydrate (GRNX) into the site of infection in patients undergoing endoscopic sinus surgery for chronic rhinosinusitis. The subjects comprised nine chronic rhinosinusitis patients who were hospitalized to undergo endoscopic sinus surgery between June 2011 and January 2012. GRNX was administered orally for 7 days prior to the surgery. On the day of surgery, we measured the concentrations of GRNX in the blood (sample collected within 3 h of the drug administration) and in tissue samples collected intraoperatively. The mean blood concentration in the nine cases was 8.06±4.41 μg/mL and the mean tissue concentration was 6.98±2.82 μg/mL. Thus, the concentration exceeded the minimum inhibitory concentrations for the main pathogenic bacteria. These results suggest that GRNX offers high tissue permeation even in the sinus mucosa, which often tends to show poor tissue permeation. Thus, GRNX is expected to have effective antimicrobial activity, making it a useful antibiotic for cases of rhinosinusitis.
